- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05331170
Viral Mucosal Reprogramming (VMR)
May 5, 2023 updated by: The University of Texas Medical Branch, Galveston
Epigenetic Mechanism Reprogramming Mucosal Anti-viral Immunity in Allergic Asthma VIRAL MUCOSAL REPROGRAMMING
This is a mechanistic, controlled, open-label, single-site study to evaluate the effects of RG-RV16 inoculation on airway mucosal gene expression and airway remodeling in 25 healthy controls (HC), in 25 allergic rhinitis subjects (AR) with cat dander allergy, and in 25 allergic asthmatic subjects (AA) with cat dander allergy.
Three groups (HC, AR, and AA) will undergo screening to establish clinical history, will undergo pulmonary function testing (spirometry), and will have blood drawn for clinical characterization (IgE, , ImmunoCAP, CBC and differential), and for assessing the presence of existing neutralizing antibody against RV16.
Only those who meet criteria will be permitted to continue into the interventional and run-out phases of the study.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
75
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Lisa Sweeney, RN
- Phone Number: 409-747-5871
- Email: lanemeth@utmb.edu
Study Locations
-
-
Texas
-
Galveston, Texas, United States, 77555
- Recruiting
- University of Texas Medical Branch
-
Contact:
- Lisa Sweeney, RN
- Phone Number: 409-747-5871
- Email: lanemeth@utmb.edu
-
Contact:
- Cindy Mitchell, CCRC
- Phone Number: 409-772-5508
- Email: cimitche@utmb.edu
-
Principal Investigator:
- William J. Calhoun, M.D
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 60 years (Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
Healthy Normal Control Group
- Subject must be able to understand and provide informed consent
- Age: 18-60 inclusive
- Sex: M or F
- No history of asthma, COPD, rhinitis, or other clinically important respiratory disease
- Non-smoker, or ex-smoker with <10 pack years, at least 5 years remote.
- No history of diabetes or cardiovascular disease
- Negative ImmunoCAP test to regionally relevant allergen panel obtained at Screening. Alternatively, documented history of a negative skin test or negative specific IgE obtained within the past 12 months.
Allergic Rhinitis Group
- Subject must be able to understand and provide informed consent
- Age: 18-60 inclusive
- Sex: M or F
- No history of asthma, COPD, or other clinically important respiratory disease
- Non-smoker, or ex-smoker with <10 pack years, at least 5 years remote
- No history of diabetes or cardiovascular disease
- History of rhinitis, physician diagnosed, plus one of the following criteria within the past 12 months
- Seasonal or perennial nasal congestion or sneezing
- Seasonal or perennial conjunctival infection or watering
- No evidence of airway obstruction (FEV1:FVC ≥ lower limit of normal)
- Positive ImmunoCAP test to cat. Documented history at any time of a positive skin test or a specific IgE measure at least Level 2 reactivity will meet this criterion. Subjects must have cat in home, have regular exposure to cat dander, or live in a home where a cat has lived within the past 6 months.
Allergic Asthma Group
Inclusion Criteria
- Subject must be able to understand and provide informed consent
- Age: 18-60 inclusive
- Sex: M or F
- No history of COPD or other clinically important respiratory disease other than asthma
- Non-smoker, or ex-smoker with <10 pack years, at least 5 years remote
- No history of diabetes or cardiovascular disease
History of mild-moderate asthma, physician diagnosed, plus one of the following criteria within the past 12 months
- Airway obstruction (FEV1: FVC <0.6) that is significantly (at least 12% change from baseline, ATS criteria) reversible after 4 puffs of albuterol (obtained at Screening Visit or documented historical testing performed with the past 12 months)
- Requiring ICS for control of asthma for at least 30 days within the past 12 months
- Positive ImmunoCAP test to cat dander. Documented history at any time of a positive skin test or a specific IgE measure at least Level 2 reactivity will meet this criteria. Subjects must have cat in home, have regular exposure to cat dander, or live in a home where a cat has lived within the past 6 months.
- Results of the CBC do not show clinically important abnormalities
Exclusion Criteria:
Healthy Group Normal Group
- Inability or unwillingness of a participant to comply with study protocol
- Currently taking inhaled corticosteroids, leukotriene modifier, or antihistamines for respiratory disease.
- Neutralizing Ab to RV16 greater than or equal to 1:8
- Pregnant or breastfeeding women or a woman who has a planned pregnancy during the course of the study. Menstruating females must have a negative pregnancy test at the screening visit. Pregnancy testing may be conducted prior to procedures as well at various times in the study.
- Subjects with household or close contacts who are pregnant or planning a pregnancy during the main subject's participation, who have chronic respiratory disease, who are children under the age of 2 years, or who are adults over 60 years of age or are Immunosuppressed e.g. post-chemotherapy, HIV).
- Subjects who provide healthcare services or work with elderly or children (e.g. daycare provider, senior citizen care giver).
Allergic Rhinitis Group
- Inability or unwillingness of a participant to comply with study protocol
- Currently using inhaled steroids, or oral montelukast for respiratory disease
- Neutralizing Ab to RV16 greater than or equal to 1:8
- Pregnant or breastfeeding women or a woman who has a planned pregnancy during the course of the study. Menstruating females must have a negative pregnancy test at screening visit. Pregnancy testing may be conducted prior to procedures as well at various times in the study.
- Subjects with household or close contacts who are pregnant or planning a pregnancy during the main subject's participation, who have chronic respiratory disease, who are children under the age of 2 years, or who are adults over 60 years of age or are Immunosuppressed e.g. post-chemotherapy, HIV) .
- Subjects who provide healthcare services or work with elderly or children (e.g. daycare provider, senior citizen care giver).
- Subjects who have received immunosuppressive treatment within the last 12 months
- BMI is greater than 35
- History of symptoms consistent with a viral URI within the past 21 days
- Results of the CBC do not show clinically important abnormalities
- Family history or medical history of liver disease or bleeding disorders
- Have not received systemic corticosteroids for 3months prior to Screening
- Antiplatelet agents other than aspirin
- Subjects who have a positive COVID-19 test will be excluded for 8 weeks
Allergic Asthma Group
- Inability or unwillingness of a participant to comply with study protocol
- Currently taking medications for respiratory diseases other than ICS, montelukast, or rescue albuterol or LABAs.
- Neutralizing Ab to RV16 greater than or equal to 1:8
- FEV1: FVC ratio less than 0.6, or FEV1 less than 60% predicted
- Recent (<30 days) exacerbation of asthma requiring systemic corticosteroids
- ICS greater than fluticasone 500 mcg/day or its equivalent (GINA 2019 table) at screening.
- Pregnant or breastfeeding women or a woman who has a planned pregnancy during the course of the study. Menstruating females must have a negative pregnancy test at screening. Pregnancy testing may be conducted prior to procedures as well at various times in the study.
- Subjects with household or close contacts who are pregnant or planning a pregnancy during the main subject's participation, who have chronic respiratory disease, who are children under the age of 2 years, or who are adults over 60 years of age or are Immunosuppressed e.g. post-chemotherapy, HIV) .
- Subjects who provide healthcare services or work with elderly or children (e.g. daycare provider, senior citizen care giver).
- Subjects who have received immunosuppressive treatment within the last 12 months
- BMI is greater than 35
- History of symptoms consistent with a viral URI within the past 21 days
- Family history or medical history of liver disease or bleeding disorders
- Have not received systemic corticosteroids for 3 months prior to Screening
- Have an ACT score >19 at the time of enrollment.
- Antiplatelet agents other than aspirin
- Subjects who have a positive COVID-19 test will be excluded for 8 weeks
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Healthy
Subjects without asthma, COPD, rhinitis and with negative allergen test
|
Exploration of the effects of RV inoculation on human airway mucosal programming in vivo
|
Active Comparator: Allergic Rhinitis
Subjects without asthma, COPD and with positive allergen test
|
Exploration of the effects of RV inoculation on human airway mucosal programming in vivo
|
Active Comparator: Allergic Ashthma
Subjects with asthma and positive allergen test
|
Exploration of the effects of RV inoculation on human airway mucosal programming in vivo
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
ZEB-1 Expression
Time Frame: Immediate
|
Q-PCR
|
Immediate
|
Type III Interferon
Time Frame: Immediate
|
Q-RT-PCR
|
Immediate
|
PD-L1 Expression
Time Frame: Immediate
|
Q-RT-PCR
|
Immediate
|
RV16 Viral Titer
Time Frame: 48 hours after inoculation
|
Plaque Assays
|
48 hours after inoculation
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
CD8 T cells in bronchoalveolar lavage fluid
Time Frame: Immediate and 48hrs post RV16 inoculation
|
Proportion and number of CD8+ T cells
|
Immediate and 48hrs post RV16 inoculation
|
Airway Remodeling
Time Frame: Immediate and 48 hrs post RV16 inoculation
|
Lamina reticularis thickness
|
Immediate and 48 hrs post RV16 inoculation
|
URI Cold Symptoms
Time Frame: Immediate and up to 7 days following inoculation
|
WURSS21 Questionnaire
|
Immediate and up to 7 days following inoculation
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: William J. Calhoun, MD, University of Texas
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 27, 2023
Primary Completion (Anticipated)
May 1, 2027
Study Completion (Anticipated)
May 1, 2027
Study Registration Dates
First Submitted
April 8, 2022
First Submitted That Met QC Criteria
April 8, 2022
First Posted (Actual)
April 15, 2022
Study Record Updates
Last Update Posted (Actual)
May 9, 2023
Last Update Submitted That Met QC Criteria
May 5, 2023
Last Verified
May 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Immune System Diseases
- Lung Diseases
- Hypersensitivity, Immediate
- Bronchial Diseases
- Otorhinolaryngologic Diseases
- Lung Diseases, Obstructive
- Respiratory Hypersensitivity
- Hypersensitivity
- Nose Diseases
- Asthma
- Rhinitis
- Rhinitis, Allergic
Other Study ID Numbers
- U01-UWM-01
- 19-0240 (Other Identifier: UTMB Record ID)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on Research Grade RG-RV
-
University of Wisconsin, MadisonNational Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health...Completed
-
University of Texas Southwestern Medical CenterSouthern Methodist UniversityRecruiting
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)Not yet recruitingBreast Cancer | Colon CancerUnited States
-
IVFarma LLCInstitute for Preventive and Social MedicineCompletedFertility Issues | Fertility Disorders | IVF | Gynecologic Disease | Reproductive Issues | Reproductive DisorderRussian Federation